Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.51 |
| ▸ | CA9 | Q16790 | 4/20 | 0.51 |
| ▸ | CA1 | P00915 | 4/20 | 0.51 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454389 | 0.93 | CA12 (0.54) | CA2CA9CA1CA12PTGER4 | |
| SCHEMBL6177377 | 0.90 | CA12 (0.49) | CA2CA9CA1CA12PTGER4 | |
| SCHEMBL6171430 | 0.87 | CA2 (0.51) | CA2CA9CA1CA12PTGER4 | |
| SCHEMBL6175056 | 0.87 | CA1 (0.43) | CA2CA9CA1CA12PTGER4 | |
| SCHEMBL6179798 | 0.87 | CA2 (0.52) | CA2CA9CA1CA12PTGER4 | |
| SCHEMBL6337114 | 0.86 | CA2 (0.51) | CA2CA9CA1CA12PTGER4 | |
| SCHEMBL4450390 | 0.82 | CA2 (0.52) | CA2CA9CA1CA12PTGER4 | |
| SCHEMBL6175253 | 0.81 | CA1 (0.53) | CA2CA9CA1CA12PTGER4 | |
| SCHEMBL6327271 | 0.81 | CA1 (0.53) | CA2CA9CA1CA12PTGER4 | |
| SCHEMBL6331794 | 0.80 | MAPT (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956050-B2 | Imidazole compounds as anti-inflammatory and analgesic agents | PFIZER, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1494667-A1 | IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | Pfizer Japan Inc. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | HIRANO MISATO (JP) | 2003-11-27 | — | — | US | disclosed |
| WO-2003086390-A1 | IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, PTGES | CA2 608/4885CA9 1390/4885CA1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.